C-WORTHY: the beginning of the rise of elbasvir and grazoprevir for the treatment of hepatitis C genotype 1 mono and HIV co-infected patients
- PMID: 27867980
- PMCID: PMC5104607
- DOI: 10.21037/atm.2016.09.22
C-WORTHY: the beginning of the rise of elbasvir and grazoprevir for the treatment of hepatitis C genotype 1 mono and HIV co-infected patients
Conflict of interest statement
Dr. Dieterich has served as a speaker as well as consultant for Merck. Dr. Sarpel has no conflicts of interest to declare.
Comment on
-
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.Lancet. 2015 Mar 21;385(9973):1087-97. doi: 10.1016/S0140-6736(14)61793-1. Epub 2014 Nov 11. Lancet. 2015. PMID: 25467560 Clinical Trial.
Similar articles
-
Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials.Lancet Gastroenterol Hepatol. 2017 Nov;2(11):805-813. doi: 10.1016/S2468-1253(17)30159-0. Epub 2017 Aug 10. Lancet Gastroenterol Hepatol. 2017. PMID: 28802816 Clinical Trial.
-
Safety and efficacy of elbasvir/grazoprevir in Asian participants with hepatitis C virus genotypes 1 and 4 infection.J Gastroenterol Hepatol. 2019 Sep;34(9):1597-1603. doi: 10.1111/jgh.14636. Epub 2019 Apr 17. J Gastroenterol Hepatol. 2019. PMID: 30779220
-
Elbasvir-grazoprevir: A new direct-acting antiviral combination for hepatitis C.Am J Health Syst Pharm. 2017 Oct 1;74(19):1533-1540. doi: 10.2146/ajhp160558. Am J Health Syst Pharm. 2017. PMID: 28947524 Review.
-
Assessment of Drug Interaction Potential Between the Hepatitis C Virus Direct-Acting Antiviral Agents Elbasvir/Grazoprevir and the Nucleotide Analog Reverse-Transcriptase Inhibitor Tenofovir Disoproxil Fumarate.Clin Pharmacol Drug Dev. 2019 Oct;8(7):962-970. doi: 10.1002/cpdd.701. Epub 2019 Jun 7. Clin Pharmacol Drug Dev. 2019. PMID: 31173674 Clinical Trial.
-
Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4.Expert Rev Clin Pharmacol. 2016 Nov;9(11):1413-1421. doi: 10.1080/17512433.2016.1233813. Epub 2016 Sep 26. Expert Rev Clin Pharmacol. 2016. PMID: 27603877 Review.
References
-
- Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012;61:1-32. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources